Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cipla Ltd. Capital/Financing Update 2025

Feb 3, 2025

59275_rns_2025-02-03_0bb52a7d-af23-4a7b-8d21-b374c22e729b.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [84 x 30] intentionally omitted <==

3[rd] February 2025

(1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Investment in Cipla Medpro South Africa Proprietary Limited, wholly owned subsidiary

Dear Sir/Madam,

In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we hereby notify that the Company will invest approx. ZAR 900 million in equity share capital of Cipla Medpro South Africa Proprietary Limited, a wholly-owned subsidiary of the Company in South Africa (“CMSA”).

Details required to be disclosed under the Listing Regulations read with Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11[th] November 2024 on the captioned subject are enclosed to this letter.

We request you to kindly take the above disclosure on record.

Thanking you, Yours faithfully,

For Cipla Limited RAJENDR Digitally signed by RAJENDRA A KUMAR KUMAR CHOPRA Date: 2025.02.03 CHOPRA 15:29:16 +05'30' Rajendra Chopra Company Secretary

Prepared by: Akshaya Kolvankar

Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail [email protected] Corporate Identity Numbe r L24239MH1935PLC002380

==> picture [84 x 30] intentionally omitted <==

Annexure – I

Details as per the SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11[th] November 2024

Sr.
No.
Particulars Details
a) Name of the target entity, details in brief
such as size, turnover, etc.
Cipla Medpro South Africa Proprietary Limited
(“CMSA”)
CMSA, is a wholly owned subsidiary of Cipla Limited,
and is the holding company for the group operations in
South Africa. The group is involved in the
manufacturing,
marketing,
and
supply
of
pharmaceutical products.
Turnover as on 31stMarch 2024:
ZAR 688.28 million
b) Whether the acquisition would fall
within related party transaction(s) and
whether
the
promoter/
promoter
group/ group companies have any
interest in the entity being acquired? If
yes, nature of interest and details
thereof and whether the same is done at
“arm’s length”
The transaction is a related party transaction and will
be at arm’s length.
None
of
the
promoter/promoter
group/group
companies have any interest in the entity.
c) Industry to which the entity being
acquired belongs
Pharmaceutical
d) Objects and impact of acquisition
(including but not limited to, disclosure
of reasons for acquisition of target
entity, if its business is outside the main
line of business of the listed entity)
The investment will be utilised to reduce inter-group
debt and improve the capital structure of CMSA and its
subsidiaries.
e) Brief details of any governmental or
regulatory approvals required for the
acquisition
Not Applicable.
f) Indicative time-period for completion of
the acquisition
The investment is expected to be completed on or
before 28thFebruary 2025 or such other date mutually
agreed between the parties.
g) Consideration
-
whether
cash
consideration or share swap or any other
form and details of the same
Cash consideration.

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail [email protected] Corporate Identity Numbe r L24239MH1935PLC002380

==> picture [84 x 30] intentionally omitted <==

h) Cost of acquisition and/or the price at
which the shares are acquired
Cost of acquisition: ZAR 899,999,992
Number of equity shares: 40,742,417
i) Percentage of shareholding / control
acquired and / or number of shares
acquired
j) Brief background about the entity
acquired in terms of products/line of
business
acquired,
date
of
incorporation, history of last 3 years’
turnover, country in which the acquired
entity has presence and any other
significant information (in brief)
Brief background: Refer (a) above.
Date of Incorporation: 15thJuly 2013
History of last 3 years turnover:
FY
Turnover
FY 2023-24
ZAR 688.28 million
FY 2022-23
ZAR 1.12 billion
FY 2021-22
ZAR 1.71 billion
Country in which CMSA has its presence: South Africa

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail [email protected] Corporate Identity Numbe r L24239MH1935PLC002380